Hutchmed Share Price (HCM)

The company will also step up independent new product research and development in China while licensing in pipelines through strategic cooperation with other drug developers, shared Lin, who is also head of the respiratory, gastrointestinal and immunology business unite of AstraZeneca China.

http://www.chinadaily.com.cn/a/202208/16/WS62fb0385a310fd2b29e72733.html

Hutchmed has moved up in the rankings following a recent re-shuffle, it's only small beans but most of the his positions percentage wise are quite small, not too far behind Innovent.

1.75% > 1.87%

https://loncarfunds.com/chna

(click view all on holdings)

http://www.chinadaily.com.cn/a/202208/08/WS62f077daa310fd2b29e70e0f.html

Informative posts, also SAFFRON Phase III trial now underway.

They will need a distributor in Europe, they have said they will cover US themselves….are they going to do a drug by drug partnership or a wider ranging deal?
..IPSEN is based in France and will own epizyme shortly….so that is another relationship to leverage….and they will be reliant on AZ for Savolitinib sales. Lilly has competing products with Innovent, and was persuaded to walk away from fruquintinib in China, so it would be strange to go back to Lilly….
All will be revealed….I just hope the partner stumps up a lot of cash upfront which will incentivise sales to make the investment pay….and cover the shortfall on Surufatinib sales which are now three years away.